MedTrace Logo

Conversion Surgery in Stage IV or Unresectable Gastric Cancer

NCT03366961 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2019-09-19

No results posted yet for this study

Summary

This study aims to identify the safety and the survival benefit of the conversion surgery in stage IV or unresectable gastric cancer. The study designed single-arm phase II trial. All the patients would undergo curative-intent radical gastrectomy after palliative chemotherapy if the tumor responded to the chemotherapy. Primary endpoint was three-year overall survival. Secondary endpoints included short-term postoperative outcomes within 30 days, three-year relapse free survival, and success rate of conversion surgery (rate of R0 resection).

Conditions

  • Stage IV or Unresectable Gastric Cancer

Interventions

PROCEDURE

Conversion surgery

Palliative chemotherapy followed by radical gastrectomy

Sponsors & Collaborators

  • The Catholic University of Korea

    collaborator OTHER

  • Peking University

    collaborator OTHER

  • Cho Hyun Park

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2019-12-31
Completion
2022-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03366961 on ClinicalTrials.gov